Table 3. Undetectable viral load achieved under LPV/r exposure in the study population.
| Totala | Group 1 | Group 2 | Group 3 | With resistance data | |
|---|---|---|---|---|---|
| Patients with available data | 194 (97.5%) | 32 (97%) | 37 (100%) | 125 (99.2%) | 64 (100%) |
| Mean time under LPV/r exposure (months) | 50.9 | 37.3 | 41.9 | 57.5 | 70.3 |
| Total number of VL measurements | 3,117 (Range: 1–48) | 438 (Range: 1–43) | 572 (Range: 1–40) | 2,107 (Range: 1–48) | 1,269 (Range:1–45) |
| Mean time between first and last available VL measurement (months) | 54.9 | 44.8 | 56.7 | 56.9 | 64.9 |
| Number of patients with baseline VL | 180 | 28 | 36 | 118 | 60 |
| Undetectable VL at baseline | |||||
| <50 | 26 | 0 | 6 | 20 | 4 |
| <200 | 33 | 0 | 8 | 25 | 4 |
| <500 | 46 | 0 | 14 | 34 | 5 |
| Number of patients with VL after LPV exposure | 194 | 32 | 35 | 125 | 64 |
| Undetectable VL at last available measurement | |||||
| <50 | 97 | 22 | 17 | 58 | 30 |
| <200 | 118 | 25 | 24 | 69 | 34 |
| <500 | 135 | 28 | 24 | 81 | 38 |
| Undetectable VL at last available measurementb | |||||
| <50 | 1,739 (55.8%) | 280 (63.9%) | 409 (71.5%) | 1,050 (49.8%) | 556 (43.8%) |
| <200 | 1,822 (58.4%) | 286 (65.3%) | 421 (73.6%) | 1,115 (52.9%) | 564 (44.4%) |
| <500 | 2,054 (65.9%) | 287 (65.5%) | 440 (76.9%) | 1,327 (63%) | 673 (53%) |
| Undetectable VL measurement per patientc | |||||
| Mean 15 (Range:0–48) | Mean 9 (Range:0–40) | Mean 12 (Range:0–37) | Mean 11 (Range: 0–29) | Mean 10.7 (Range: 0–38) | |
| 59.6% IQR [22–92.3] | 49.5% IQR [9.4–83.7] | 68.3% IQR [50–91.7] | 56.9% IQR [24.9–87.9] | 44% IQR [0–81.1] |
aNo available data for 5 patients (1 in group 1, 1 in group 2 and 3 not ascribed to any group because of the lack of information).
bUndetectable VL considering values of <50, <200 and <500 HIV-1-RNA copies/ml, depending on available commercial VL technique used for HIV quantification at sample processing time.
cUndetectable VL as <500 HIV-1-RNA copies/ml; VL, viral load; IQR, interquartile range; no., number.